CTOs on the Move

Harpoon Therapeutics

www.harpoontx.com

 
Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.harpoontx.com
  • 611 Gateway Boulevard Suite 400
    South San Francisco, CA USA 94080
  • Phone: 650.443.7400

Executives

Name Title Contact Details

Funding

Harpoon Therapeutics raised $45M on 05/25/2017
Harpoon Therapeutics raised $70M on 11/12/2018

Similar Companies

AZPerio

AZPerio is home to the state’s leading board-certified periodontists, expertly guided by a patient-first philosophy and collaborative approach. With eight locations throughout Arizona, we are committed to client service, clinical excellence and providi...

Manhattan Research

Manhattan Research is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ISK Biosciences Corporation

ISK Biosciences Corporation is a Painesville, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PharmaCord

PharmaCord is the key connector between manufacturers, patients, physicians and payors. We provide innovative solutions that drive efficient and rapid access to life saving therapies. At PharmaCord, we help biopharma companies by delivering tailored solutions that alleviate product access hurdles and drive commercial success. Programs are configured with a focus on key stakeholders in a product`s success including physicians, patients and payors. Services are accessed through our CAPS (Centralized Access Patient Services) Center. Rapid uptake and continuation of therapy are the results our clients see. While the name of the company is new, our leadership is not. Over the years our team has provided support to millions of patients and driven commercial success for our client`s products. The leadership team of the company have led the launch of over 40 different products and transitioned dozens of programs spanning a 20-year period.

Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company`s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.